NEW YORK (GenomeWeb News) – Biocartis and BioMérieux on Thursday announced a mutual agreement to end their alliance to develop and commercialize the integrated molecular biology system called Idylla.

All rights to the platform, formerly called Apollo and developed by Biocartis in collaboration with Philips Corporate Technologies, will be returned to Biocartis, which will have all rights to Idylla now related to its use in the microbiology field, Biocartis said. The company also is free to explore new strategic options for the platform in the microbiology field, it added.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.